MGMonica Gianoli

Monica Gianoli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Gianoli has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hybrid Coronary Revascularization Versus On-Pump Coronary Artery Bypass Grafting: The Dutch Experience

    by Roos de Jong, Monica Gianoli, Maaike Roefs, Sandeep Singh, Patrique Segers, Michiel Voskuil, Pim van der Harst, Willem Suyker, Kirolos Jacob

    Objective: Hybrid coronary revascularization (HCR) is minimally invasive coronary artery bypass surgery in patients with multivessel disease. This study compared the clinical outcomes of robot-assisted HCR patients with those receiving conventional on-pump coronary artery bypass grafting (CABG) in the Netherlands. Methods: We included 117 HCR and 2,160 CABG patients between January 2015 and December 2021. We performed a 1:3 propensity score matching (PSM) analysis. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events (MACCE) at ≤30 days of follow-up. Secondary outcomes included red blood cell transfusions, length of stay, and the individual components of MACCE, which were mortality, perioperative myocardial infarction, revascularization of the target vessel (TVR), kidney failure, and in-hospital ischemic cerebrovascular accidents. Mortality and TVR at midterm follow-up were also included. Results: After PSM, 115 HCR and 342 on-pump CABG patients were included. HCR patients underwent a mean ± standard deviation of 1 ± 0 distal anastomosis, whereas CABG patients had a mean of 3.6 ± 1.1 distal anastomoses. At ≤30 days of follow-up, no differences in MACCE (odds ratio [OR] = 1.27, 95% confidence interval [CI]: 0.48 to 2.88, P = 0.57) or in the individual secondary outcomes were found. HCR resulted in a shorter hospital stay (OR = 0.99, 95% CI: 0.99 to 1.0, P = 0.02). At a median of 35 months (interquartile range [IQR], 23 to 45) of follow-up in the HCR group and 34 months (IQR, 22 to 45) in the CABG group, all-cause mortality and TVR did not differ. Conclusions: HCR provides excellent short-term and midterm outcomes, comparable to conventional CABG, while also offering faster recovery.

  • EACTS Expert Consensus Document on Robotic Cardiac Surgery Minimum Standards for Programme Implementation, Training and Quality Assurance, developed in collaboration with EACTAIC and EBCP

    by Wouter Oosterlinck, Meindert Palmen, Monica Gianoli, Milan Milojevic, Jan Bekaert, Friedhelm Beyersdorf, Filip P A Casselman, Karlien Degezelle, Volkmar Falk, Thierry Folliguet, et al.

    Robotic cardiac surgery is entering a renewed phase of adoption, supported by growing clinical experience, evolving robotic platforms, and rising demand for less invasive procedures and faster recovery. However, implementation remains technically demanding and resource-intensive and can expose patients to avoidable harm when initiated without a structured training programme, clear technical standards, and rigorous outcome monitoring. This expert consensus document summarizes the current state of robotic cardiac surgery and defines requirements for the safe, effective, and sustainable development of robotic cardiac programmes. It addresses the current regulatory environment for surgical robots and accessories and proposes minimum requirements for hardware, software, and instruments for reconstructive intracardiac and coronary cardiac procedures. Furthermore, it outlines prerequisites for starting and developing training centres, including surgeon experience, multidisciplinary team composition, patient selection, and institutional infrastructure and volume considerations. A stepwise, competency-based training pathway is presented that integrates video and live case observation, virtual and simulation-based skills acquisition, wet/dry laboratory training, and proctored clinical implementation, ideally supported by dual-console systems. The document emphasises the need for transparent documentation and outcome benchmarking via a society-driven database to support quality assurance, learning-curve oversight, and continuous improvement. Finally, it highlights priorities for further research, including harmonized reporting standards, long-term and procedure-specific outcome evaluation, and prospective studies assessing training models, cost-effectiveness, and the incremental value of emerging technologies.

  • Open Access

    PKP2 orchestrates OXPHOS expression in cardiomyocytes via a PGC1α-dependent mechanism

    by Su Ji Han, Daphne van Den Berg, Hesther de Ruiter, Hoyee Tsui, Eirini Kyriakopoulou, Tim Koopmans, Ilaria Perini, Jantine Monshouwer-Kloots, Sebastiaan J van Kampen, Anneline S J M Te Riele, et al.

    Aims: Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease in which most patients carry (likely) pathogenic variants in desmosomal genes, most commonly in plakophilin-2 (PKP2). While the genetic causes are well described, the molecular mechanisms driving disease progression—particularly in response to exercise—remain poorly understood. Methods and results: To investigate disease-driving pathways in ACM, we used PKP2 mutant human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and myocardial tissue from ACM patients. Transcriptomic profiling revealed consistent downregulation of oxidative phosphorylation (OXPHOS) genes in PKP2 mutant hiPSC-CMs, which was confirmed in explanted ACM hearts carrying PKP2 variants. Reduced expression of OXPHOS-related genes was associated with lower PPARGC1A expression and decreased mitochondrial spare capacity in PKP2 mutant hiPSC-CMs. The reduction in PPARGC1A expression appeared to result, at least in part, from decreased AMPKα protein levels, a known activator of PPARGC1A previously shown to localize at the intercalated disc, as PKP2 mutant cells failed to increase PPARGC1A expression following treatment with AICAR, an AMPK activator. To directly assess whether increasing PPARGC1A expression could compensate for this defect, we overexpressed PPARGC1A, which partially restored OXPHOS gene expression and improved contractility in PKP2 mutant cells. Conclusion: Our study identifies a novel transcriptional mechanism linking PKP2 loss to reduced mitochondrial function via decreased PGC1α signaling, partially through reduced AMPKα levels. Disruption of this axis reduces OXPHOS gene expression and mitochondrial function in PKP2 mutant hiPSC-CMs, potentially impairing the heart’s ability to meet increased energy demands during stress, and offering a mechanistic explanation for the detrimental effects of exercise in ACM. Furthermore, these findings highlight PGC1α induction as a potential therapeutic strategy to restore OXPHOS gene expression and mitochondrial adaptability in ACM.


  • Open Access

    Nationwide Short-Term and Midterm Clinical Outcome Comparison of Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Surgery

    by Monica Gianoli, Anne R. de Jong, Ferenc van der Hulst, Maaike M. Roefs, Sandeep Singh, Patrique Segers, Pim van der Harst, Willem J.L. Suyker, Kirolos A. Jacob

    Objective: Hybrid coronary revascularization (HCR) has emerged as a minimally invasive alternative to conventional coronary artery bypass techniques for patients with multivessel coronary artery disease. This study aimed to compare the clinical outcomes of HCR versus off-pump coronary artery bypass (OPCAB) in patients with multivessel disease in The Netherlands. Methods: This study analyzed 117 HCR patients and 313 OPCAB patients after propensity score matching. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events (MACCE) at 30 days after the procedure. Secondary outcomes included mortality, myocardial infarction, repeat revascularization, and ischemic cerebrovascular accidents. Midterm survival and repeat target vessel revascularization (TVR) were evaluated over a median follow-up of 36 months. Results: At 30 days, MACCE rates were similar between the HCR group (5.1%) and the OPCAB group (4.1%; P = 0.62). Secondary outcomes were also comparable between the groups. The incidence of myocardial infarction in the HCR group was numerically higher (3.4% vs 1.6%), but this difference was not statistically significant ( P = 0.17). Midterm survival rates showed no significant difference between the groups, although numerically the HCR showed a higher rate of TVR (5.1% vs 4.1%, P = 0.62). No significant differences were found in blood transfusion requirements or postoperative hospital stay duration. Conclusions: HCR demonstrated comparable short-term and midterm outcomes to OPCAB, suggesting it is a viable alternative for multivessel coronary artery disease treatment. However, further research is necessary to assess long-term effectiveness and to identify specific patient populations who may benefit most from HCR.

  • Advancing coronary artery revascularization by robotics and automated connector technology

    by Monica Gianoli

    Coronary artery bypass grafting (CABG) has remained the most durable treatment for advanced coronary artery disease for more than six decades. Its long-term success is largely attributable to the use of the left internal mammary artery (LIMA) to bypass the left anterior descending artery (LAD), which provides superior patency and survival benefits compared with other revascularization strategies. Despite its proven effectiveness, conventional CABG is associated with substantial surgical trauma due to sternotomy and the frequent use of cardiopulmonary bypass. In an era increasingly focused on patient-centered care, sustainability, and healthcare efficiency, these limitations have prompted renewed interest in less invasive alternatives that preserve surgical durability. This thesis explores how robotic-assisted, minimally invasive, and hybrid coronary revascularization strategies can bridge the gap between durability and invasiveness. Rather than framing coronary revascularization as a binary choice between percutaneous coronary intervention (PCI) and CABG, the work adopts an integrated perspective in which surgical and percutaneous techniques are combined in a patient-tailored manner. The central hypothesis is that hybrid and robotic-assisted approaches can retain the biological advantages of surgical grafting while reducing surgical trauma, procedural variability, and system-level burden. Part I evaluates clinical outcomes of minimally invasive direct coronary artery bypass grafting (MIDCAB), robotic-assisted MIDCAB (RA-MIDCAB), and hybrid coronary revascularization (HCR). A meta-analysis comparing MIDCAB with PCI for isolated proximal LAD disease confirms the durability of the LIMA–LAD graft and suggests a potential long-term survival advantage of surgical revascularization. Nationwide registry analyses from the Netherlands demonstrate that HCR achieves mid-term outcomes comparable to conventional CABG and off-pump CABG (OPCAB) in selected patients, while offering advantages in recovery and perioperative morbidity. These findings support a shift toward more nuanced patient selection rather than procedural replacement. Part II examines the economic and environmental implications of robotic-assisted coronary surgery. Cost analyses indicate that although robotic platforms require substantial upfront investment, these costs may be offset by reduced hospital stays and faster recovery. Environmental assessments highlight meaningful differences in resource use and waste generation between revascularization strategies, emphasizing that sustainability considerations become relevant when clinical outcomes are comparable. Part III places robotic coronary surgery within a broader European context, identifying structural barriers to adoption, including training requirements, regulatory heterogeneity, and the absence of enabling technologies. Part IV addresses this limitation through the development and preclinical evaluation of the Octocon, a novel automated coronary connector designed to overcome the hemodynamic and biological shortcomings of earlier devices. Ex vivo testing demonstrates feasible, reproducible anastomoses within a fully endoscopic robotic setting, supporting its potential role as an enabling technology for totally endoscopic coronary artery bypass (TECAB). In conclusion, this thesis demonstrates that coronary revascularization is evolving toward a more integrated, patient-centered, and sustainable paradigm. By combining clinical evidence, system-level evaluation, and technological innovation, it provides a framework for preserving the strengths of surgical revascularization while adapting it to the demands of modern healthcare.

  • Open Access

    Combining Surgical and Percutaneous Revascularization for Multivessel Coronary Artery Disease: The Case for a Hybrid Approach

    by Samuel Heuts, Pim van der Harst, Erika Nodin, Joakim Grant Frederiksen, Patrique Segers, Fabrizio Rosati, Johan Bennett, Arpad Lux, Steven Jacobs, Monica Gianoli, et al.


  • Open Access

    Ex vivo Sealing Performance of a Sutureless Dual-Component Connector for Coronary Bypass

    by Monica Gianoli, Harmen M Wassink, Leonard J van Schelven, Paul F Gründeman, Willem J L Suyker

    Sutureless coronary connectors may enable minimally invasive bypass surgery, but consistent sealing in human vessels remains a key challenge. This ex vivo study evaluates the hydrostatic performance of a titanium connector that employs a novel sealing principle: tissue-to-metal coaptation enabling stepwise distal anastomosis construction. Thirteen anastomoses were created in porcine and human cadaveric vessels using a standardized three-step deployment protocol. Target sites included internal mammary arteries, saphenous veins, and coronary arteries, selected for suitability for hand-suturing. Sealing was assessed by hydrostatic pressure testing up to 300 mmHg. Key anatomical parameters and procedural outcomes were recorded. Twelve of 13 anastomoses were completed without leakage up to 300 mmHg; one case exhibited minor oozing at 260 mmHg. The connector accommodated vessels down to 1.3 mm in diameter and up to 0.8 mm wall thickness. One misdeployment due to an oversized incision was corrected intraoperatively without compromising the hydrostatic result. Visual inspection confirmed wide, unobstructed anastomotic orifices. This ex vivo evaluation demonstrates that the connector achieved consistent hydrostatic sealing through bare-metal vessel coaptation, even in small-diameter human coronary tissue. These findings support further in vivo validation towards minimally invasive coronary bypass applications.

  • Open Access

    Coronary Connector Facilitated Total Endoscopic Coronary Artery Bypass: An Ex Vivo Feasibility Study

    by Monica Gianoli, Anne Roos de Jong, Harmen Matthijs Wassink, Paul F. Gründeman, Bob Kiaii, Husam H. Balkhy, Willem J. L. Suyker

    Objective: Totally endoscopic coronary artery bypass (TECAB) procedures pose significant challenges, motivating the development of Octocon, an automated endoscopic connector designed for coronary anastomoses in off-pump and endoscopic settings. This feasibility study aimed to assess Octocon’s functionality and maneuverability in closed-chest conditions during robot-assisted TECAB simulations. Methods: The Octocon deployment comprises a 3-step procedure. Initially, delicate self-aligning microstapling technology is used to attach connector halves to individual blood vessels. Subsequently, the connector halves are joined to accomplish the anastomosis process. TECAB conditions were simulated using a dedicated box housing ex vivo porcine hearts. The study, conducted by 3 experienced surgeons, investigated the feasibility and standardization potential of a robot-assisted procedure employing Octocon. It evaluated maneuverability in closed-chest conditions and assessed the effectiveness of grafting internal mammary artery segments to different heart regions using single graft, jump graft, and Y-graft constructions. Results: The robot-assisted procedure, using 4 standard instruments, successfully completed all 3 steps in 18 anastomotic procedures. In 96% of cases, the procedural steps were accomplished on the first attempt. The feasibility of constructing jump graft and Y-graft geometries on both anterior and posterior heart walls was demonstrated. Furthermore, experiences affirmed the device’s endoscopic user-friendliness, ease of teachability, reproducibility, and potential to achieve expedient, leak-free anastomoses. Conclusions: This ex vivo study confirmed Octocon’s potential suitability and functionality for TECAB. The device can create diverse grafting strategies and achieve wide-open vascular connections on various heart regions, highlighting its potential in advancing minimally invasive, robot-assisted coronary procedures. These promising results justify further exploration for integration into clinical practice.


  • European Association of Cardiothoracic Surgeons future view on robotic cardiac surgery in Europe

    by Wouter Oosterlinck, Monica Gianoli, Meindert Palmen, Thierry Folliguet, Johannes Bonatti, Alfonso Agnino, Sandeep Singh, Ulrich Franke, Paul Modi, Daniel Pereda, et al.

    The implementation of robotic surgical systems has reduced the invasive nature of certain cardiac surgical procedures over the recent decades. In the early days, coronary artery bypass grafting (CABG) and mitral valve repair (MVR) were mostly performed through a conventional sternotomy approach. Over time, however, minimally invasive techniques, including endoscopic methods, have become routine, particularly for MVR and MIDCAB procedures. The introduction of robotic surgical systems in the 1990s further advanced these techniques, offering valuable opportunities for continued innovation. This evolution is also closely linked with Enhanced Recovery After Cardiac Surgery (ERACS) and other related concepts that have become integral to modern cardiac surgery. However, technical, logistic and cost-related issues, related to the robotic platform, have hampered and slowed down the widespread adoption of the robotic CABG procedure [ 1]. Innovations and especially technical ones do not emerge gradually and constantly but come in waves. In the beginning, innovations are almost always cumbersome, unreliable, expensive and without any convenient infrastructure, e.g. printing press, electricity, railroads, cars, computers. The dissemination of innovations is therefore costly, slow, risky and entails drastic changes in behaviour [ 2]. After many decades, the introduction of an innovation may look perfectly smooth and easy. However, every innovation must fight against existing interests, established knowledge and those who staunchly defend both. Fear and mistrust of everything new and different are endemic.


  • Open Access

    Cost Analysis of Robot-Assisted Versus On-Pump and Off-Pump Coronary Artery Bypass Grafting: A Single-Center Surgical and 30-Day Outcomes Comparison

    by Monica Gianoli, Anne R. de Jong, Pim van der Harst, Niels P. van der Kaaij, Kirolos A. Jacob, Willem J. L. Suyker

    Objective: Throughout Europe, the interest in implementing robot-assisted minimally invasive direct coronary artery bypass (RA-MIDCAB) has been growing. However, concerns about additional costs have emerged concurrently. In this analysis, we aim to provide a comparison of the cumulative perioperative costs of RA-MIDCAB, on-pump coronary artery bypass grafting (CABG), and off-pump CABG (OPCAB). Methods: We conducted a propensity score–matched analysis comparing patients undergoing RA-MIDCAB with those undergoing CABG or OPCAB at our institution from January 2016 to December 2021. After matching, we analyzed the combined intraoperative surgical costs and 30-day postoperative costs. We first compared RA-MIDCAB costs to CABG and then to OPCAB separately. Violin plots illustrated the cost distribution among individual patients. Total cost uncertainty was estimated using 1,000 bootstrapping iterations. Results: Seventy-nine RA-MIDCAB patients were matched to 158 CABG patients, and 80 RA-MIDCAB patients were matched to 149 OPCAB patients. Considering both surgical and clinical outcomes, RA-MIDCAB yielded an average cost of €17,121 per patient (€16,781 to €33,294), CABG was €16,571 per patient (€16,664 to €41,860), and OPCAB was €15,463 per patient (€10,895 to €57,867). After bootstrap iterations, RA-MIDCAB was found to be €472 (2.8%) and €1,599 (10.3%) more expensive per patient than CABG and OPCAB, respectively. Conclusions: In The Netherlands, the adoption of RA-MIDCAB did not show a significant economic impact on hospital resources. The additional robotic costs for the surgery were almost entirely offset by the cost savings during the postoperative hospital stay. However, these comparisons may differ when considering hybrid coronary revascularization with its additional percutaneous coronary intervention costs.